Kaare Meier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kaare Meier has a total of 301 co-authors. Here are the top co-authors by number of shared publications:
- Jens Christian Hedemann Sørensen
Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark
15 shared publications - Lone Nikolajsen
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
7 shared publications Jens Christian Hedemann Sørensen
6 shared publications- Andreas Nørgaard Glud
Center of Excellence in Focused Ultrasound, Department of Neurosurgery Aarhus University Hospital Aarhus Denmark
5 shared publications - Ida Stisen Fogh‐Andersen
Department of Neurosurgery Aarhus University Hospital Aarhus Denmark
5 shared publications - Rigmor Højland Jensen
Department of Neurology, Danish Headache Center, Copenhagen University Hospital – Rigshospitalet
4 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in Movement Disorders
Focused Ultrasound for Essential Tremor in Denmark: Results After 1 Year of Follow‐Up
Background: Essential tremor (ET) is the most common hyperkinetic movement disorder. Magnetic resonance‐guided focused ultrasound thalamotomy (MRgFUSTh) has become an established therapy in drug‐refractory tremor as one treatment option. Here, we present the results of a large cohort of MRgFUSTh‐treated ET patients followed‐up 1 year post‐ablation. Objective: The primary endpoint durability of tremor reduction at 12 months at this timepoint. Methods: This was a single‐hospital cohort study. Prior to, and 12 months after, treatment, patients were rated according to the Fahn–Tolosa–Marin (FTM) scale, Quality of Life in Essential Tremor (QUEST) scale, Patient Global Assessment of Change (PGIC), as well as general health, well‐being, and factors relating to social and everyday activities. Finally, side effects and adverse event data were collected at 12 months. Results: The current cohort comprised 111 patients. Patients showed good response to MRgFUSTh with a mean decrease of 29.5 points in the total FTM‐score from pretreatment (95% CI: 26.3; 32.8, P < 0.0001) corresponding to 62.4% (95% CI: 56.4%; 68.5%). This meant a reduction in the FTM‐score of 13.8 points (± 5.2 points, 95% CI: 12.79; 14.73, P < 0.00001) or 85.2% (±24.2%, 95% CI: 80.70%; 89.78%) in the treated limb. For QUEST, symptoms improved by 20.9 points (95% CI: 12.1; 29.6, P < 0.0001) corresponding to a relative improvement of 54% (95% CI: 33.2%; 75.5%). Conclusion: Results showed clear and persistent tremor improvements as assessed by both clinicians and patients. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 26 October 2026
- Published by Wiley in Movement Disorders
Open AccessFocused Ultrasound for Essential Tremor in Denmark: Results After 1 Year of Follow‐Up
Background: Essential tremor (ET) is the most common hyperkinetic movement disorder. Magnetic resonance‐guided focused ultrasound thalamotomy (MRgFUSTh) has become an established therapy in drug‐refractory tremor as one treatment option. Here, we present the results of a large cohort of MRgFUSTh‐treated ET patients followed‐up 1 year post‐ablation. Objective: The primary endpoint durability of tremor reduction at 12 months at this timepoint. Methods: This was a single‐hospital cohort study. Prior to, and 12 months after, treatment, patients were rated according to the Fahn–Tolosa–Marin (FTM) scale, Quality of Life in Essential Tremor (QUEST) scale, Patient Global Assessment of Change (PGIC), as well as general health, well‐being, and factors relating to social and everyday activities. Finally, side effects and adverse event data were collected at 12 months. Results: The current cohort comprised 111 patients. Patients showed good response to MRgFUSTh with a mean decrease of 29.5 points in the total FTM‐score from pretreatment (95% CI: 26.3; 32.8, P < 0.0001) corresponding to 62.4% (95% CI: 56.4%; 68.5%). This meant a reduction in the FTM‐score of 13.8 points (± 5.2 points, 95% CI: 12.79; 14.73, P < 0.00001) or 85.2% (±24.2%, 95% CI: 80.70%; 89.78%) in the treated limb. For QUEST, symptoms improved by 20.9 points (95% CI: 12.1; 29.6, P < 0.0001) corresponding to a relative improvement of 54% (95% CI: 33.2%; 75.5%). Conclusion: Results showed clear and persistent tremor improvements as assessed by both clinicians and patients. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 4 August 2026
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
Examining the latency effect in chronic pain patients treated with spinal cord stimulation. A follow-up study to the open, interventional, investigator-initiated, international multicenter EChO study.
- 4 August 2026
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
Open AccessExamining the latency effect in chronic pain patients treated with spinal cord stimulation. A follow-up study to the open, interventional, investigator-initiated, international multicenter EChO study.
- Open Access
- 19 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (6) , 1442-1457
Combined patch-clamp electrophysiology and single-cell genomic analysis reveal spiking tumor cells at the neocortical glioblastoma interface in humans
Background: Electrophysiological features of glioblastoma cells (GBCs) remain largely elusive, challenging our comprehension of glioblastoma pathophysiology. Spiking GABAergic-oligodendrocyte-progenitor (OPC) tumor cells were recently described in IDH-mutant glioma, correlating with prolonged patient survival. Here, we characterize single-cell features at the neocortical leading edge (LE) of glioblastoma patients using combined electrophysiological, morphological, and transcriptomic profiling. Methods: We examined GBCs and non-tumor cells using acute and cultured organotypic slices of cancer-infiltrated neocortical tissues from glioblastoma patients. Electrophysiological properties of LE cells were investigated using whole-cell patch-clamp recording, with dye loading to characterize single-cell morphology. We used Patch-seq to determine the transcriptomic features of recorded LE cells and discriminate tumor and non-tumor cells, followed by gene set enrichment analysis and CellChat to identify differential gene expression and signaling. Results: Upon depolarization, more than half of LE cells show aberrant action potentials (aAPs), akin to neurodevelopmental cells. Reconstructed LE cells have abnormal somatodendritic morphology. Patch-seq revealed that GBCs and non-tumor cells share a similar electrophysiological phenotype, including aAP generation, depolarized membrane potential, and elevated input resistance. Transcriptomic analysis shows that the aAP phenotype occurs across diverse GBC states and correlates with lower enrichment of proliferation-related pathways at the single-cell level, but higher enrichment of inflammatory/immune, angiogenic, and mesenchymal transition pathways. Non-tumor cells exhibit hybrid transcriptomic signatures, with predominantly neuronal but minor enrichment of astrocytic features. Conclusion: We find electrophysiological aAP behavior of GBCs in human glioblastoma, closely resembling that of hybrid cells in IDH-mutant glioma, supporting the hypothesis of neuronal mimicry across different glioma types.
- 19 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (6) , 1442-1457
Open AccessCombined patch-clamp electrophysiology and single-cell genomic analysis reveal spiking tumor cells at the neocortical glioblastoma interface in humans
Background: Electrophysiological features of glioblastoma cells (GBCs) remain largely elusive, challenging our comprehension of glioblastoma pathophysiology. Spiking GABAergic-oligodendrocyte-progenitor (OPC) tumor cells were recently described in IDH-mutant glioma, correlating with prolonged patient survival. Here, we characterize single-cell features at the neocortical leading edge (LE) of glioblastoma patients using combined electrophysiological, morphological, and transcriptomic profiling. Methods: We examined GBCs and non-tumor cells using acute and cultured organotypic slices of cancer-infiltrated neocortical tissues from glioblastoma patients. Electrophysiological properties of LE cells were investigated using whole-cell patch-clamp recording, with dye loading to characterize single-cell morphology. We used Patch-seq to determine the transcriptomic features of recorded LE cells and discriminate tumor and non-tumor cells, followed by gene set enrichment analysis and CellChat to identify differential gene expression and signaling. Results: Upon depolarization, more than half of LE cells show aberrant action potentials (aAPs), akin to neurodevelopmental cells. Reconstructed LE cells have abnormal somatodendritic morphology. Patch-seq revealed that GBCs and non-tumor cells share a similar electrophysiological phenotype, including aAP generation, depolarized membrane potential, and elevated input resistance. Transcriptomic analysis shows that the aAP phenotype occurs across diverse GBC states and correlates with lower enrichment of proliferation-related pathways at the single-cell level, but higher enrichment of inflammatory/immune, angiogenic, and mesenchymal transition pathways. Non-tumor cells exhibit hybrid transcriptomic signatures, with predominantly neuronal but minor enrichment of astrocytic features. Conclusion: We find electrophysiological aAP behavior of GBCs in human glioblastoma, closely resembling that of hybrid cells in IDH-mutant glioma, supporting the hypothesis of neuronal mimicry across different glioma types.
- Open Access
- 9 March 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Safety and efficacy of occipital nerve stimulation as treatment of chronic cluster headache: an investigator-initiated, double-blind, randomized, placebo-controlled study
Occipital nerve stimulation has shown promising results in attack prevention in patients with chronic cluster headache, but evidence from controlled trials
- 9 March 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Open AccessSafety and efficacy of occipital nerve stimulation as treatment of chronic cluster headache: an investigator-initiated, double-blind, randomized, placebo-controlled study
Occipital nerve stimulation has shown promising results in attack prevention in patients with chronic cluster headache, but evidence from controlled trials
- Open Access
- 29 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Spinal cord stimulation therapy for gait impairment in Parkinson’s disease: a double-blinded, randomised feasibility trial with an open extension
A trial of spinal cord stimulation (SCS) was performed in people with gait-impaired Parkinson’s (ClinicalTrials.gov: NCT05110053). Fourteen patients underwent gait assessments and [18F]-FDG and [18F]-FEOBV PET at baseline, six, and twelve months after SCS. Twelve participants were randomised to six-month MicroBurst or sham, followed by six-month extension with stimulation. The primary outcomes were feasibility and safety, as captured by the trial process measures and nature and frequency of adverse events, respectively, and the Postural Instability and Gait Disorder (PIGD) score as a clinical outcome. Secondary outcomes included assessments of balance and gait at home and at visits, including the Lower Body and Gait (LBG) score, imaging, and patient-reported outcomes of changes in gait, balance and quality of life. Seventeen patients (12%) were eligible for enrolment. Recruitment was feasible (1.2 participants/month) and SCS was well-tolerated. At six months, MicroBurst did not significantly improve gait compared with sham, although bradykinesia/rigidity improved. At 12 months, LBG scores improved (−4.31 points, p = 0.0012) with bilateral decreased thalamic metabolism and decreased right anterior insula [18F]-FEOBV uptake. The trial met its primary feasibility and safety endpoints by achieving recruitment targets and demonstrating that SCS was well-tolerated. However, it did not meet the primary clinical endpoint of a significant PIGD improvement at six months. Larger trials are warranted, as SCS may improve LBG and leg rigidity/bradykinesia, especially as time progresses. We reported data for power calculations and identified important risks for designing future trials.
- 29 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSpinal cord stimulation therapy for gait impairment in Parkinson’s disease: a double-blinded, randomised feasibility trial with an open extension
A trial of spinal cord stimulation (SCS) was performed in people with gait-impaired Parkinson’s (ClinicalTrials.gov: NCT05110053). Fourteen patients underwent gait assessments and [18F]-FDG and [18F]-FEOBV PET at baseline, six, and twelve months after SCS. Twelve participants were randomised to six-month MicroBurst or sham, followed by six-month extension with stimulation. The primary outcomes were feasibility and safety, as captured by the trial process measures and nature and frequency of adverse events, respectively, and the Postural Instability and Gait Disorder (PIGD) score as a clinical outcome. Secondary outcomes included assessments of balance and gait at home and at visits, including the Lower Body and Gait (LBG) score, imaging, and patient-reported outcomes of changes in gait, balance and quality of life. Seventeen patients (12%) were eligible for enrolment. Recruitment was feasible (1.2 participants/month) and SCS was well-tolerated. At six months, MicroBurst did not significantly improve gait compared with sham, although bradykinesia/rigidity improved. At 12 months, LBG scores improved (−4.31 points, p = 0.0012) with bilateral decreased thalamic metabolism and decreased right anterior insula [18F]-FEOBV uptake. The trial met its primary feasibility and safety endpoints by achieving recruitment targets and demonstrating that SCS was well-tolerated. However, it did not meet the primary clinical endpoint of a significant PIGD improvement at six months. Larger trials are warranted, as SCS may improve LBG and leg rigidity/bradykinesia, especially as time progresses. We reported data for power calculations and identified important risks for designing future trials.
- Open Access
- 28 November 2025
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 29 (1) , 129-138
Management of Pregnancy in Patients With an Implanted Spinal Cord Stimulator: A European Expert Survey
- 28 November 2025
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 29 (1) , 129-138
Open AccessManagement of Pregnancy in Patients With an Implanted Spinal Cord Stimulator: A European Expert Survey
- 2 November 2025
- Published by Wiley in European journal of pain
- Vol. 29 (10) , e70160
Societal Cost Analysis of Spinal Cord Stimulation in Chronic Pain Patients: A Danish Register‐Based Study With 3 Years Follow‐Up
Background: Spinal cord stimulation (SCS) constitutes a treatment option for patients with severe chronic pain responding insufficiently to pharmacological treatment. High device costs and expenses associated with surgical procedures and follow‐up constitute a barrier to adoption. However, CNP patients also constitute a significant burden on public finances, with high public costs relating to health care utilisation, medicine, and lost work capacity. Methods: We investigated the costs of SCS therapy from a healthcare perspective (primary and secondary healthcare and medicine costs) 3 years before and 3 years after initiation of the SCS therapy in a large, mixed, well‐characterised patient cohort derived from a dedicated neuromodulation registry, including patients with different diagnoses and characteristics from three of the four Danish SCS centers. We additionally compared costs of productivity loss for patients under the age of retirement. Data on societal costs were retrieved from public Danish registries. Results: Three hundred and eight‐four patients were included. Total healthcare costs 3 years after SCS were significantly higher than 3 years before SCS, with an increase of €29,835. The expenses associated with establishing SCS therapy are reflected in a sharp increase in in‐patient secondary health care cost in year one after SCS. Primary health care, secondary out‐patient health care and medicine costs all decrease after SCS but not enough to compensate for the cost of establishing treatment. Costs due to productivity loss remain stable throughout the period. Conclusions: Our findings highlight evaluating high‐cost interventions within a broader cost framework to inform more efficient resource allocation in chronic pain management. Significance: This study analyzes the real‐world socioeconomic impact of spinal cord stimulation (SCS) in Denmark. By using data from public Danish registries, we find a sharp increase in in‐hospital expenses at the year of implantation, only partially offset by a subsequent reduction in other health care expenses and medicine costs. These findings give unique insights into the financial aspects of SCS, offering a perspective for healthcare providers, policymakers, and patients when evaluating the long‐term budgetary implications of this treatment.
- 2 November 2025
- Published by Wiley in European journal of pain
- Vol. 29 (10) , e70160
Societal Cost Analysis of Spinal Cord Stimulation in Chronic Pain Patients: A Danish Register‐Based Study With 3 Years Follow‐Up
Background: Spinal cord stimulation (SCS) constitutes a treatment option for patients with severe chronic pain responding insufficiently to pharmacological treatment. High device costs and expenses associated with surgical procedures and follow‐up constitute a barrier to adoption. However, CNP patients also constitute a significant burden on public finances, with high public costs relating to health care utilisation, medicine, and lost work capacity. Methods: We investigated the costs of SCS therapy from a healthcare perspective (primary and secondary healthcare and medicine costs) 3 years before and 3 years after initiation of the SCS therapy in a large, mixed, well‐characterised patient cohort derived from a dedicated neuromodulation registry, including patients with different diagnoses and characteristics from three of the four Danish SCS centers. We additionally compared costs of productivity loss for patients under the age of retirement. Data on societal costs were retrieved from public Danish registries. Results: Three hundred and eight‐four patients were included. Total healthcare costs 3 years after SCS were significantly higher than 3 years before SCS, with an increase of €29,835. The expenses associated with establishing SCS therapy are reflected in a sharp increase in in‐patient secondary health care cost in year one after SCS. Primary health care, secondary out‐patient health care and medicine costs all decrease after SCS but not enough to compensate for the cost of establishing treatment. Costs due to productivity loss remain stable throughout the period. Conclusions: Our findings highlight evaluating high‐cost interventions within a broader cost framework to inform more efficient resource allocation in chronic pain management. Significance: This study analyzes the real‐world socioeconomic impact of spinal cord stimulation (SCS) in Denmark. By using data from public Danish registries, we find a sharp increase in in‐hospital expenses at the year of implantation, only partially offset by a subsequent reduction in other health care expenses and medicine costs. These findings give unique insights into the financial aspects of SCS, offering a perspective for healthcare providers, policymakers, and patients when evaluating the long‐term budgetary implications of this treatment.
- 20 December 2024
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 65 (6) , 973-982
Transcutaneous electrical nerve stimulation of the occipital nerves as treatment for chronic cluster headache
Background: Chronic cluster headache (CCH) is an excruciatingly painful condition that can be difficult to treat sufficiently with the available medical treatment options. The greater occipital nerves (GON) are of major interest in treating CCH, and various invasive treatment modalities, such as stimulating or blocking the nerves, have been applied. Because the terminal segment of the GON has a superficial course, the nerve is also accessible for non‐invasive transcutaneous stimulation. Transcutaneous electrical nerve stimulation (TENS) has been suggested as a treatment for different chronic headaches, but evidence of the efficacy in patients with CCH is scarce. Additionally, no consensus exists on the optimal placement of the transcutaneous stimulation electrodes or the treatment usage pattern. Methods: In this explorative open‐label clinical study, 36 patients with CCH were treated with TENS of the GON for 8–12 consecutive weeks between August 2021 and October 2023 as a separate part of the study protocol for a trial on stimulation of the GON (Clinicaltrials.gov identifier: NCT05023460). After a baseline period, TENS was used primarily as a preventive treatment, stimulating for 30 min twice daily at a minimum. The primary outcome was a change in attack frequency and safety with TENS treatment. Secondary outcomes were change in attack duration and pain intensity on the numeric rating scale, abortive treatments, and the Patient Global Impression of Change (PGIC) with TENS treatment. The change in attack frequency, duration, pain intensity, and use of abortive treatment was analyzed by comparing the baseline data with 4‐weekly data from TENS treatment. The study aimed to systematically investigate the effect of TENS of the GON as a preventive treatment for CCH. Results: Weekly attack frequency decreased from a median of 15.7 (95% confidence interval [CI] 11.2–22.1) at baseline to 11.0 (95% CI 7.4–16.4) with TENS. In all, 13 of the 36 (36%) patients had a minimum 30% reduction in attack frequency. In the group of 30% responders, the number of weekly attacks decreased from 15.8 (95% CI 9.8–24.5) at baseline to 5.8 (95% CI 3.3–10.5) attacks with TENS. Five patients became entirely or nearly attack‐free. For the entire cohort, attack duration and pain intensity were also significantly reduced with TENS. The use of oxygen was reduced by 42%, and triptan injections decreased by 55%. Overall, 15 (42%) patients reported a clinically important improvement with TENS treatment, rated on the PGIC scale. The 100 Hz stimulation programs were preferred over 10 Hz. No serious adverse events were registered. Conclusion: Transcutaneous electrical nerve stimulation of the GON significantly reduced the frequency, intensity, and duration of weekly headache attacks in patients with severe CCH. Not all patients benefitted from TENS, but the treatment responders had a substantial improvement in their cluster headache. TENS treatment was well‐tolerated with little or no side effects and could be a relevant supplement to conventional preventive treatment. A standard TENS apparatus is low cost, making the treatment accessible to most patients. This paper includes a detailed, comprehensive description of our clinical application of the therapy.
- 20 December 2024
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 65 (6) , 973-982
Transcutaneous electrical nerve stimulation of the occipital nerves as treatment for chronic cluster headache
Background: Chronic cluster headache (CCH) is an excruciatingly painful condition that can be difficult to treat sufficiently with the available medical treatment options. The greater occipital nerves (GON) are of major interest in treating CCH, and various invasive treatment modalities, such as stimulating or blocking the nerves, have been applied. Because the terminal segment of the GON has a superficial course, the nerve is also accessible for non‐invasive transcutaneous stimulation. Transcutaneous electrical nerve stimulation (TENS) has been suggested as a treatment for different chronic headaches, but evidence of the efficacy in patients with CCH is scarce. Additionally, no consensus exists on the optimal placement of the transcutaneous stimulation electrodes or the treatment usage pattern. Methods: In this explorative open‐label clinical study, 36 patients with CCH were treated with TENS of the GON for 8–12 consecutive weeks between August 2021 and October 2023 as a separate part of the study protocol for a trial on stimulation of the GON (Clinicaltrials.gov identifier: NCT05023460). After a baseline period, TENS was used primarily as a preventive treatment, stimulating for 30 min twice daily at a minimum. The primary outcome was a change in attack frequency and safety with TENS treatment. Secondary outcomes were change in attack duration and pain intensity on the numeric rating scale, abortive treatments, and the Patient Global Impression of Change (PGIC) with TENS treatment. The change in attack frequency, duration, pain intensity, and use of abortive treatment was analyzed by comparing the baseline data with 4‐weekly data from TENS treatment. The study aimed to systematically investigate the effect of TENS of the GON as a preventive treatment for CCH. Results: Weekly attack frequency decreased from a median of 15.7 (95% confidence interval [CI] 11.2–22.1) at baseline to 11.0 (95% CI 7.4–16.4) with TENS. In all, 13 of the 36 (36%) patients had a minimum 30% reduction in attack frequency. In the group of 30% responders, the number of weekly attacks decreased from 15.8 (95% CI 9.8–24.5) at baseline to 5.8 (95% CI 3.3–10.5) attacks with TENS. Five patients became entirely or nearly attack‐free. For the entire cohort, attack duration and pain intensity were also significantly reduced with TENS. The use of oxygen was reduced by 42%, and triptan injections decreased by 55%. Overall, 15 (42%) patients reported a clinically important improvement with TENS treatment, rated on the PGIC scale. The 100 Hz stimulation programs were preferred over 10 Hz. No serious adverse events were registered. Conclusion: Transcutaneous electrical nerve stimulation of the GON significantly reduced the frequency, intensity, and duration of weekly headache attacks in patients with severe CCH. Not all patients benefitted from TENS, but the treatment responders had a substantial improvement in their cluster headache. TENS treatment was well‐tolerated with little or no side effects and could be a relevant supplement to conventional preventive treatment. A standard TENS apparatus is low cost, making the treatment accessible to most patients. This paper includes a detailed, comprehensive description of our clinical application of the therapy.
- 28 November 2024
- Published by Wiley in Pain Practice
- Vol. 25 (1)
Occipital nerve stimulation: A detailed description of a surgical approach and a discussion on implantation techniques
Objective: Occipital Nerve Stimulation (ONS) is increasingly used to treat a range of chronic, refractory headache conditions, most notably chronic cluster headache (CCH).Despite this, there is still no consensus on the optimal implantation technique. Clinical reports and reviews in the field have reported remarkably high complication rates of which several can be directly related to the surgical approach.We here describe a comprehensive and detailed surgical approach used at Aarhus University Hospital, Denmark, aiming to improve paresthesia coverage and minimize complications.Methods: The implantation procedure described here is performed with a sleep‐awake anesthetic regimen in a lateral position using anatomical landmarks and perioperative testing based on patient feedback. A single lead is subcutaneously implanted from behind the ear and across the back of the head, and the implantable pulse generator (IPG) is placed below the right clavicle.Results: From March 2018 to June 2024, 45 CCH patients were implanted using this approach and followed up for a total of 86.3 patient years. A total of 22 adverse events (AEs) occurred in 17 patients, with nine AEs requiring revision surgery. Notably, no instances of lead migration, lead breakage, or muscle/neck stiffness were observed. Temporary occipital dysesthesia was the most frequent non‐surgical AE, resolving spontaneously within weeks. The rate of serious adverse events (SAEs) was one per 9.6 patient years. Six patients had the ONS system explanted due to lack of efficacy.Conclusions: The surgical approach described here in detail offers several advantages, with a favorable complication profile, satisfactory paresthesia coverage, and good perioperative patient comfort. Advances in the surgical technique are vital to both patients and healthcare providers, and we believe this approach is a valuable contribution toward improved patient outcomes and procedural efficiency.
- 28 November 2024
- Published by Wiley in Pain Practice
- Vol. 25 (1)
Occipital nerve stimulation: A detailed description of a surgical approach and a discussion on implantation techniques
Objective: Occipital Nerve Stimulation (ONS) is increasingly used to treat a range of chronic, refractory headache conditions, most notably chronic cluster headache (CCH).Despite this, there is still no consensus on the optimal implantation technique. Clinical reports and reviews in the field have reported remarkably high complication rates of which several can be directly related to the surgical approach.We here describe a comprehensive and detailed surgical approach used at Aarhus University Hospital, Denmark, aiming to improve paresthesia coverage and minimize complications.Methods: The implantation procedure described here is performed with a sleep‐awake anesthetic regimen in a lateral position using anatomical landmarks and perioperative testing based on patient feedback. A single lead is subcutaneously implanted from behind the ear and across the back of the head, and the implantable pulse generator (IPG) is placed below the right clavicle.Results: From March 2018 to June 2024, 45 CCH patients were implanted using this approach and followed up for a total of 86.3 patient years. A total of 22 adverse events (AEs) occurred in 17 patients, with nine AEs requiring revision surgery. Notably, no instances of lead migration, lead breakage, or muscle/neck stiffness were observed. Temporary occipital dysesthesia was the most frequent non‐surgical AE, resolving spontaneously within weeks. The rate of serious adverse events (SAEs) was one per 9.6 patient years. Six patients had the ONS system explanted due to lack of efficacy.Conclusions: The surgical approach described here in detail offers several advantages, with a favorable complication profile, satisfactory paresthesia coverage, and good perioperative patient comfort. Advances in the surgical technique are vital to both patients and healthcare providers, and we believe this approach is a valuable contribution toward improved patient outcomes and procedural efficiency.
- 1 July 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (8) , 447-448
Spinal cord stimulation for the treatment of chronic pain
- 1 July 2024
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 20 (8) , 447-448
Spinal cord stimulation for the treatment of chronic pain